Try our Advanced Search for more refined results

Expert Analysis

A Shifting Trend In FDA Form 483 Disclosure Obligations

By Brett Jaffe, Timothy Fitzmaurice and Sierra Shear ( August 22, 2025, 5:08 PM EDT) -- The U.S. District Court for the Southern District of New York's May 19 decision in In re: Checkpoint Therapeutics Securities Litigation extends a streak of dismissals of securities class actions alleging that pharmaceutical companies failed to disclose U.S. Food and Drug Administration Form 483 inspection reports....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Law Firms

Companies

Government Agencies